All In Biotech

Drug Trial Radar · NCT05480657

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

AT-1501-I206: An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Transplanted Islet Cells and AT-1501 Immunomodulation in Adults With Brittle Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Sep 30, 2022

Primary completion

Aug 2024

Study completion Aug 2028

Sponsor

Lead sponsor
Eledon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Conditions

  • Brittle Type 1 Diabetes Mellitus

Interventions

  • AT-1501 IV InfusionBiological

    Investigational study drug

  • Isolated cadaveric islet cellsBiological

    Infusion of human cadaveric islet cells into the portal vein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)Time frame: Accessed from date of transplant through Day 364 post final transplant for approximately 2 years
  2. Efficacy - Insulin independenceTime frame: Date of transplant through Day 364 post- final transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.